Clinical Cancer Research, Vol 3, Issue 11 2039-2046, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alteration in bcl-xL and bak expression

QY Liu and CA Stein
Department of Medicine and Pharmacology, Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA.

bcl-xL is an antiapoptotic protein that shares sequence homology with bcl-2 and seems to convey chemoresistance in many human tumor cell lines. bcl-xL protein is expressed at a 3-fold higher level in PC-3 cells than it is in LNCaP cells. Taxol causes apoptosis in both these cell lines, as measured by the formation of DNA ladders and by the observation of typical cellular morphological changes (chromatin condensation and nuclear fragmentation) after 4', 6-diamidino-2-phenylindole staining. Overexpression of bcl-2 in LNCaP cells did not prevent Taxol-induced apoptosis. Treatment of LNCaP cells with 10 nm Taxol led, after 24 h, to relatively specific and almost total down-regulation of bcl-xL protein in the absence of alteration of bax, bak, or bcl-2 levels. This change was paralleled by a similar decrease in the level of bcl-xL mRNA, as demonstrated by reverse transcription-PCR. The level of glyceraldehyde-3-phosphate dehydrogenase mRNA was not changed. In PC-3 cells, 48 h were required for both maximal bcl-xL protein down-regulation and cellular apoptosis. In contrast, treatment of LNCaP cells with estramustine induced apoptosis, but this was not associated with any change in the intracellular level of bcl-xL or bax protein. Instead, relatively specific 2-fold up-regulation of the proapoptotic protein bak was observed. In PC-3 cells, cellular apoptosis induced by estramustine was bak independent. These results augment our understanding of the importance of bcl-xL in prostate cancer and suggest that appropriate manipulation of cytotoxic chemotherapeutic agents may favorably alter the balance between pro- and antiapoptotic proteins in this tumor.

This article has been cited by other articles:

				M. L. Nguyen, R. M. Kraft, and J. A. Blaho Susceptibility of cancer cells to herpes simplex virus-dependent apoptosis J. Gen. Virol., July 1, 2007; 88(7): 1866 - 1875. [Abstract] [Full Text] [PDF]

				D. Sarkar, I. V. Lebedeva, Z.-z. Su, E.-S. Park, L. Chatman, N. Vozhilla, P. Dent, D. T. Curiel, and P. B. Fisher Eradication of Therapy-Resistant Human Prostate Tumors Using a Cancer Terminator Virus Cancer Res., June 1, 2007; 67(11): 5434 - 5442. [Abstract] [Full Text] [PDF]

				C. Castilla, B. Congregado, D. Chinchon, F. J. Torrubia, M. A. Japon, and C. Saez Bcl-xL Is Overexpressed in Hormone-Resistant Prostate Cancer and Promotes Survival of LNCaP Cells via Interaction with Proapoptotic Bak Endocrinology, October 1, 2006; 147(10): 4960 - 4967. [Abstract] [Full Text] [PDF]

				M. N. Fishman, C. R. Garrett, G. R. Simon, A. A. Chiappori, R. M. Lush, W. R. Dinwoodie, J. J. Mahany, A. M. Dellaportas, A. Cantor, A. Gollerki, et al. Phase I Study of the Taxane BMS-188797 in Combination with Carboplatin Administered Every 3 Weeks in Patients with Solid Malignancies Clin. Cancer Res., January 15, 2006; 12(2): 523 - 528. [Abstract] [Full Text] [PDF]

				A. Belkhiri, A. Zaika, N. Pidkovka, S. Knuutila, C. Moskaluk, and W. El-Rifai Darpp-32: a Novel Antiapoptotic Gene in Upper Gastrointestinal Carcinomas Cancer Res., August 1, 2005; 65(15): 6583 - 6592. [Abstract] [Full Text] [PDF]

				Y. Li, X. Hong, M. Hussain, S. H. Sarkar, R. Li, and F. H. Sarkar Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells Mol. Cancer Ther., March 1, 2005; 4(3): 389 - 398. [Abstract] [Full Text] [PDF]

				N. Kikuno, N. Moriyama-Gonda, T. Yoshino, T. Yoneda, S. Urakami, M. Terashima, M. Yoshida, H. Kishi, K. Shigeno, H. Shiina, et al. Blockade of Paclitaxel-Induced Thymidine Phosphorylase Expression Can Accelerate Apoptosis in Human Prostate Cancer Cells Cancer Res., October 15, 2004; 64(20): 7526 - 7532. [Abstract] [Full Text] [PDF]

				A. R. Jazirehi, X.-H. Gan, S. De Vos, C. Emmanouilides, and B. Bonavida Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis Mol. Cancer Ther., November 1, 2003; 2(11): 1183 - 1193. [Abstract] [Full Text] [PDF]

				D. J. Taxman, J. P. MacKeigan, C. Clements, D. T. Bergstralh, and J. P-Y. Ting Transcriptional Profiling of Targets for Combination Therapy of Lung Carcinoma with Paclitaxel and Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase Inhibitor Cancer Res., August 15, 2003; 63(16): 5095 - 5104. [Abstract] [Full Text] [PDF]

				S. Ray and A. Almasan Apoptosis Induction in Prostate Cancer Cells and Xenografts by Combined Treatment with Apo2 Ligand/Tumor Necrosis Factor-related Apoptosis-inducing Ligand and CPT-11 Cancer Res., August 1, 2003; 63(15): 4713 - 4723. [Abstract] [Full Text] [PDF]

				L. Drew, R. L. Fine, T. N. Do, G. P. Douglas, and D. P. Petrylak The Novel Antimicrotubule Agent Cryptophycin 52 (LY355703) Induces Apoptosis via Multiple Pathways in Human Prostate Cancer Cells Clin. Cancer Res., December 1, 2002; 8(12): 3922 - 3932. [Abstract] [Full Text] [PDF]

				R. Kwan, J. Burnside, T. Kurosaki, and G. Cheng MEKK1 Is Essential for DT40 Cell Apoptosis in Response to Microtubule Disruption Mol. Cell. Biol., November 1, 2001; 21(21): 7183 - 7190. [Abstract] [Full Text] [PDF]

				P. A. Hershberger, W.-D. Yu, R. A. Modzelewski, R. M. Rueger, C. S. Johnson, and D. L. Trump Calcitriol (1,25-Dihydroxycholecalciferol) Enhances Paclitaxel Antitumor Activity in Vitro and in Vivo and Accelerates Paclitaxel-induced Apoptosis Clin. Cancer Res., April 1, 2001; 7(4): 1043 - 1051. [Abstract] [Full Text]

				X. Li, M. Marani, R. Mannucci, B. Kinsey, F. Andriani, I. Nicoletti, L. Denner, and M. Marcelli Overexpression of BCL-XL Underlies the Molecular Basis for Resistance to Staurosporine-induced Apoptosis in PC-3 Cells Cancer Res., February 1, 2001; 61(4): 1699 - 1706. [Abstract] [Full Text]

				D.-C. Yu, Y. Chen, J. Dilley, Y. Li, M. Embry, H. Zhang, N. Nguyen, P. Amin, J. Oh, and D. R. Henderson Antitumor Synergy of CV787, a Prostate Cancer-specific Adenovirus, and Paclitaxel and Docetaxel Cancer Res., January 1, 2001; 61(2): 517 - 525. [Abstract] [Full Text]

				I. Lebedeva, R. Rando, J. Ojwang, P. Cossum, and C. A. Stein Bcl-xL in Prostate Cancer Cells: Effects of Overexpression and Down-Regulation on Chemosensitivity Cancer Res., November 1, 2000; 60(21): 6052 - 6060. [Abstract] [Full Text]

				M. Garzotto, A. Haimovitz-Friedman, W.-C. Liao, M. White-Jones, R. Huryk, W. D. W. Heston, C. Cardon-Cardo, R. Kolesnick, and Z. Fuks Reversal of Radiation Resistance in LNCaP Cells by Targeting Apoptosis through Ceramide Synthase Cancer Res., October 1, 1999; 59(20): 5194 - 5201. [Abstract] [Full Text] [PDF]

				C. Dumontet and B. I. Sikic Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell Death J. Clin. Oncol., March 1, 1999; 17(3): 1061 - 1061. [Abstract] [Full Text] [PDF]

				D. R. Mercatante, C. D. Bortner, J. A. Cidlowski, and R. Kole Modification of Alternative Splicing of Bcl-x Pre-mRNA in Prostate and Breast Cancer Cells. ANALYSIS OF APOPTOSIS AND CELL DEATH J. Biol. Chem., May 4, 2001; 276(19): 16411 - 16417. [Abstract] [Full Text] [PDF]

				J. E. Chipuk, M. Bhat, A. Y. Hsing, J. Ma, and D. Danielpour Bcl-xL Blocks Transforming Growth Factor-beta 1-induced Apoptosis by Inhibiting Cytochrome c Release and Not by Directly Antagonizing Apaf-1-dependent Caspase Activation in Prostate Epithelial Cells J. Biol. Chem., July 6, 2001; 276(28): 26614 - 26621. [Abstract] [Full Text] [PDF]